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RETROSPECTIVE COMPARISON OF PHENYTOIN AND LEVETIRACETAM AS
SEIZURE PROPHYLAXIS WITH HIGH DOSE BUSULFAN DURING ALLOGE-
NEIC STEM CELL TRANSPLANT
Mathew, S.1, Harnicar, S.1, Adel, N.1, Papadopoulos, E.2 1Memorial
Sloan-Kettering Cancer Center, New York, NY; 2Memorial Sloan-
Kettering Cancer Center, New York, NY
Background: Busulfan is an alkylating agent commonly used in pre-
parative regimens for hematopoietic stem cell transplant (HSCT).
Early clinical trials, prior to the use of seizure prophylaxis, revealed
a high degree of neurotoxicity associated with myeloablative doses of
this agent. Phenytoin has been widely used as seizure prophylaxis
with busulfan. However, potential concerns with its use include
the length of time to achieve a therapeutic steady state, risk of hep-
atotoxicity, and drug-drug interactions with busulfan and other
agents used during conditioning. Alternatively, levetiracetam is
highly bioavailable in both oral and intravenous forms, with a short
half life it rapidly achieves steady state and is renally eliminated with
limited drug interactions. The main objective of this study was to
compare the incidence of seizures with phenytoin and levetiracetam.
Secondary objectives were to compare VOD incidence, assess busul-
fan and phenytoin pharmacokinetics, and toxicity of the prophylactic
agents.
Methods: All patients$ 18 years of age receiving busulfan in a pre-
parative regimen prior to HSCT between 6/1/08-6/30/09 were in-
cluded in this retrospective analysis. Patient information was
collected from the pharmacy database and electronic medical re-
cords. Data included age, disease, preparative regimen, type of trans-
plant, busulfan dose, busulfan AUC, survival status, incidence of
relapse, and hepatic panels.
Results: 54 patients were included in this analysis with 22 receiving
phenytoin and 32 receiving levetiracetam as seizure prophylaxis.
Phenytoin was dosed with a 1000 mg loading dose and 300 mg
daily maintenance dose. Levetiracetam was dosed at 500 mg twice
daily. Of the 54 patients there were no reports of seizures in either
group. There were also no reports of VOD in either group. Eleva-
tion in liver enzymes occurred in 3 (9%) patients who received lev-
etiracetam compared to 7 (32%) patients who received phenytoin.
A therapeutic steady state of phenytoin was achieved in 12 (55%)
patients. Twenty patients (63%) receiving levetiracetam needed bu-
sulfan dose adjustments based on pharmacokinetic analysis versus
11 (50%) receiving phenytoin. Rates of relapse were similar in
both groups.
Conclusion: Levetiracetam is a safe and effective alternative to phe-
nytoin for busulfan seizure prophylaxis. With low hepatoxicity, no
pharmacokinetic monitoring, and limited drug-drug interactions it
is an attractive option in the HSCT population.558
WEIGHT-BASED DOSING OF VALGANCICLOVIR IN PEDIATRIC HSCT RE-
CIPIENTS
Nguyen, N.-Y.1, Puebla, M.1, Krance, R.A.2 1Texas Children’s Hospital,
Houston, TX; 2Baylor College of Medicine, Houston, TX
Background: IV ganciclovir is the standard therapy to prevent CMV
infection in HSCT recipients at Texas Children’s Hospital. In 2001,
the FDA approved valganciclovir (VGC) for treatment of CMV ret-
initis in AIDS patients. This oral preparation increased the oral bio-
availability of ganciclovir from 5% to 60% and demonstrated a well
established safety profile. The oral route of administration avoids the
need for a central line and markedly decreases the added costs asso-
ciated with IV therapy. Unfortunately, data as to the efficacy of VGC
to preventCMV infection in pediatricHSCT recipients is limited. In
2004, our institution reported positive experience in liver transplant
patients using 15–18 mg/kg/dose. Encouraged by this result, the
HSCT program began using a similar dosing strategy for patients
unable to receive IV ganciclovir. This report evaluates the efficacyand safety of weight-based dosing of VGC for CMV prophylaxis
in pediatric HSCT recipients.
Methods: Thus far, we have evaluated thirty-two patients (2-20
years old) for this retrospective study. The inclusion criteria were: al-
logeneic HSCT recipients, CMV seropositive (donor and/or recip-
ient) prior to transplantation, received VGC $ 7 days. Exclusion
criteria were: ANC\ 500 and renal dysfunction. Efficacy was de-
fined as no incidence of CMV reactivation during therapy based
upon the development of CMV antigenemia or the presence of
CMV by quantitative PCR (qPCR). ANC served as a marker for
safety. The dosing was as follows: 15-18 mg/kg/dose (max 900 mg)
twice daily for 14 days, then once daily thereafter.
Results:Thedurationof therapy ranged 7days to2 years.The average
dose for patients\60 kgwas 15.2mg/kg/dose (8.2– 22.5mg/kg/dose.)
Patients$ 60 kg received a maximum 900 mg per dose. CMV reacti-
vationwas not observed in 30of 32 patients.Therapywas discontinued
in 4 patients due to declining ANC. Four patients required filgrastim
intermittently to maintain ANC. 500. Effect on ANC cannot be as-
sessed for one patient due to concurrent treatment with hydroxyurea.
Most importantly, no patient developed CMV pneumonitis.
Conclusion:Our data demonstrate that valganciclovir 15 – 18mg/kg/
dose is effective and safe as a CMV prophylactic regimen in pediatric
HSCT patients. However, frequent monitoring, including CMV
qPCR and hematologic profile, is necessary with VGC therapy.559
USE OF HEPATITIS B IMMUNE GLOBULIN AND ADEFOVIR IN A CORD
BLOOD TRANSPLANT RECIPIENT
DiMicco, M.G., Ahmed, T. Westchester Medical Center, Valhalla, NY
A 52-year old female with acute myelogenous leukemia in remis-
sion presented for a matched unrelated donor hematopoeitic stem
cell transplant, testing negative for Hepatitis B surface antigen.
The recipient underwent HPCT conditioning using the Slavin reg-
imen. The patient’s human leukocyte antigen (HLA) typingmatched
with a cord blood donation from a twin birth where the mother was
found to be Hepatitis B surface antigen positive; the HBsAg status of
the twin donors was unknown at the time of hematopoeitic stem cell
transplantation.
As a precaution against the recipient developing a Hepatitis B in-
fection, Hepatitis B Immune Globulin and Adefovir was adminis-
tered as chemoprophylaxis. Dosing of Hepatitis B Immune
Globulin was derived from the liver transplant literature. Hepatitis
B Immune Globulin 20,000 international units was given intrave-
nously on transplant day zero and repeated on transplant days 1
through 7. Additional doses were scheduled for every two weeks
to begin on transplant day +14. Adefovir 10 mg was ordered to
be administered by mouth daily beginning on transplant day nega-
tive 2.
On transplant day +19 the HBsAg status of the twin donors was
discovered to be negative.Hepatitis B chemoprophylaxis was discon-
tinued at that time with no additional doses administered to the re-
cipient.
Hepatitis B Immune Globulin is used in the liver transplantation
population to prevent hepatitis B virus recurrence inHBsAg-positive
recipients after transplantation. Adefovir is used to treat chronic hep-
atitis B infections.560
DECLINE IN BONE MINERAL DENSITY IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: IMPACT OF MYELOABLATIVE VERSUS
REDUCED INTENSITY CONDITIONING REGIMENS
McCullough, K.B.1, Burzynski, J.A.1, Hogan, W.J.2, Litzow, M.R.2,
Wolf, R.C.1, Wermers, R.A.3 1Mayo Clinic, Rochester, MN; 2Mayo
Clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN
Background:Comparedwithmyeloablative (MA) regimens, reduced
intensity conditioning (RIC) regimens have shown a lower incidence
of some complications (veno-occlusive disease, pre-engraftment in-
fections, bronchiolitis obliterans); however, the incidence is similar
for others (chronic kidney disease, hypothyroidism). The incidence
of osteoporosis and osteopenia has not been compared.
